PDDI Task Force - minutes and recording from the 9/21 Content sub-team meeting

Dear Colleagues,

I hope your fall is going well so far.  have pasted the (belated) 
minutes and link to the recording for the 9/21 Content sub-team meeting 
of the PDDI Information Model Task Force (https://goo.gl/74mCgV).

Some other follow-ups:

- We have pretty much all of the content for the Introductory W3C 
Interest Group Note drafted but in rough form (see the google docs 
linked to this page: https://goo.gl/PYK5rQ). I am behind on cleaning up 
the content and editing it into the actual note and could use some help 
with that. Please let me know if you are interested in helping.

- The Content sub-team has another meeting scheduled for  10/18 at 1pm 
Eastern.

- There are currently no meetings for the Standard sub-team. I plan to 
send a doodle poll out for that next.

best, -R

---


    Minutes for 9/21/2016 (Content Meeting)

In Attendance:  Dan Malone, John Horn, Jeff Nielson, Richard Boyce, 
Brian LeBaron, Evan Draper

Meeting recording: https://goo.gl/1yRbSe

Meeting:

  *

    Decision tree status

      o

        Evan

          +

            Tyrosine kinase inhibitors + proton pump inhibitors

              #

                Update: just PPI data required, additional data included

              #

                Only did BCR-ABL inhibitors – demonstrate pH dependence

              #

                Waiting to hear from MAOI on tree feedback

              #

                Need to explain explicit data

                  *

                    Who made the decision tree and what comments?

          +

            Warfarin + etoposide/ifosfamide: draft

              #

                Include DIPS data

              #

                Look for indirect evidence for possible mechanisms

      o

        Dan

          +

            Tamoxifen + paroxetine

              #

                Went through literature with respects to various
                antidepressants to categorize inhibition to 2D6 as it
                relates to Tamoxifen metabolism

                  *

                    Focused on small set of antidepressants

              #

                Come up with solid evidence for AUC percent changes and
                potential inhibitors

              #

                Table is accurate with current time

              #

                Discuss further at the next meeting

      o

        John

          +

            Amiodarone + simvastatin

              #

                Issue: what is the cut off dose for simvastatin?

              #

                Simple decision tree

              #

                Change red diamond for simvastatin at any dose

              #

                Change <20mg to yellow

              #

                Generalize in footnote it is preferable to not mix
                amiodarone and simvastatin

          +

            Fluconazole + simvastatin: discuss at the next meeting

  *

    Next Steps

      o

        Continue to revise decision trees

          +

            Discuss - Tamoxifen + paroxetine (finish), Fluconazole +
            simvastatin (new)


-- 
Richard D Boyce, PhD
Associate Professor of Biomedical Informatics and Clinical and Translational Science in the Clinical and Translational
Science Institute
Faculty, Center for Pharmaceutical Policy and Prescribing
Faculty, Geriatric Pharmaceutical Outcomes and Gero-Informatics Research and Training Program
University of Pittsburgh
rdb20@pitt.edu
Office: 412-648-9219
Twitter: @bhaapgh